IFRX (InflaRx) Short-Term Debt to Capital

InflaRx N.V. (IFRX) is a recognized leader in immunology, developing critical treatments to suppress acute inflammatory processes. This price visualization featuring the 0.01 metric assists in the fundamental asset valuation and complements the analysis of antibody development for rare autoimmune diseases, where patent protection guarantees multi-year revenue. The company's financial foundation rests on significant capital, enabling it to conduct clinical trials of complement inhibitors independently of market volatility.

Export challenges for immunological innovations driven by geopolitical fragmentation require InflaRx N.V. (IFRX) to maintain strict liquidity control to sustain its research. The ratio of liabilities maturing within one year to equity measures short-term financial risk, allowing an assessment of the balance sheet's dependence on operational borrowing and the probability of a solvency crisis through the company's short-term leverage history.